Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 11:55 AM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Stock Picks » Strong Buy: 1H09 Clinical Trial Information



Reply
 
Thread Tools Search this Thread
Old 05-28-2009, 09:49 AM   Nav to Top  #1
mahmissa
UberTrader
 
mahmissa's Avatar
 
Join Date: May 2009
Location: Washington
Posts: 294
Favorites: BAC, HEB, LVS
Rep Power: 235
Reputation: 2450
mahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond reputemahmissa has a reputation beyond repute
Default 1H09 Clinical Trial Information

Hi all- I am trying to provide some information about clinical trials for stocks trading under $10. Stocks frequently have big surges when trial infromation is successful, especially in stage III trials.

Clinical trial data dates are not fixed the way FDA decision dates are. They are estimates. I am posting information on 1H09 clinical trials in this thread. When it is complete, I will tackle 2H09.

I will keep editing this initial post as I add more information, which I will do daily. Please do your own DD.

1H09
LGND
LGND - Ligand Pharmaceuticals Inc. - Google Finance
Expected 1H09 resubmission for Vivant to prevent post-menopausal osteoporosis.
Most recent earnings news:
http://www.marketwatch.com/story/10-...inc?dist=msr_2

2Q09
MELA
MELA - Electro-Optical Sciences, Inc. - Google Finance
MELA has a binding protoagreementment with FDA for Melafindfind as a new diagnosscreeningnign for melanoma, which includes expedited review (180 days expected) for the company's PMA (pre-market approval application). MELA expects to file the PMA in 2Q09. On 5/9/08, MELA announced a $45 million CEFF (committed equity financing facility) with Kingsbridge Capital Limited which provides the company with the option to acces up to $45 million in financing through the sale of newly issued stock over the next three years.
American Chronicle | EOS Secures $45 Million Committed Equity Financing Facility
� Biogen Idec, Electro-Optical Among “5 Stocks Approaching Greatness” | OneMedPlace � Archive


2Q09
MNTA
MNTA - Momenta Pharmaceuticals, Inc. - Google Finance
MNTA's proprietary anti-coagulate Phase II clinical trial results are due late 2Q2009. MNTA is the leader in deciphering and analyzing the intricacies of complex mixture therapeutics. Although complex mixture therapeutics account for tens of billions of dollars in annual sales, they have historically been poorly understood, preventing would-be generic makers from describing them in sufficient detail to gain approval under an ANDA. Momenta is poised to gain the first approval for a complex mixture generic (directed to blockbuster Lovenox / enoxaparin), with an ANDA filed for a second (directed to blockbuster Copaxone / glatimer acetate), and preparations being made for the filing of a third (specific target unknown)."
Wedbush Morgan initaties coverage, $15 fair price value http://www.streetinsider.com/New+Coverage/Wedbush+Morgan+Initiates+Coverage+on+Momenta+Pharm aceuticals+(MNTA)+with+a+Buy%3B+Fair+Value+$15/4666608.html


GLTY'A!
__________________
Mahmissa

May you live all the days of your life- Jonathon Swift

Last edited by mahmissa; 05-28-2009 at 10:36 AM..
mahmissa is offline   2 thumbs up / 0 thumbs down. Rate this post Yes | No Reply With Quote
Reply

Tags
bipharma, FDA, LGND, MELA


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On